Latest News on LUNG

Financial News Based On Company


Advertisement
Advertisement

Lucid Capital Markets Starts Pulmonx Corp. (LUNG) at Buy, PT $7, 'Turnaround Priced as a Broken Therapy'

https://www.streetinsider.com/Analyst+Comments/Lucid+Capital+Markets+Starts+Pulmonx+Corp.+%28LUNG%29+at+Buy%2C+PT+%247%2C+Turnaround+Priced+as+a+Broken+Therapy/27366318.html
Lucid Capital Markets initiated coverage on Pulmonx Corp. (NASDAQ: LUNG) with a Buy rating and a $7.00 price target. Analyst Alex Nowak believes the company is undervalued, priced as a "broken therapy," despite recent positive management changes. Nowak highlights that the return of former CEO Glen French and COO/CFO Derrick Sung, who were instrumental in the company's initial success, addresses previous execution issues.

Lucid Capital Markets initiates Pulmonx stock with buy rating By Investing.com

https://in.investing.com/news/stock-market-news/lucid-capital-markets-initiates-pulmonx-stock-with-buy-rating-93CH-5712153
Lucid Capital Markets has initiated coverage on Pulmonx Corp. (NASDAQ:LUNG) with a Buy rating and a $7.00 price target, noting the stock is undervalued despite recent gains. The firm attributes past challenges to execution issues, not the Zephyr therapy, and highlights strong Q3 revenue driven by a returning management team that has spurred significant stock appreciation and a return to year-over-year growth.

A treatment may make lung-valve therapy possible for emphysema patients once ruled out

https://www.stocktitan.net/news/LUNG/pulmonx-announces-publication-of-convert-trial-results-for-aeri-seal-xsva6i174pc6.html
Pulmonx announced the publication of results from its CONVERT trial, demonstrating that its AeriSeal system successfully converted collateral ventilation in 75.8% of evaluable severe emphysema patients, enabling subsequent Zephyr Valve treatment. This breakthrough could allow a broader group of patients to benefit from minimally invasive lung volume reduction. The company is now enrolling patients in the CONVERT II pivotal trial to further evaluate AeriSeal's safety and effectiveness and support a U.S. FDA Premarket Approval application.

Form SCHEDULE 13G/A Pulmonx Corp Filed by: PRIMECAP MANAGEMENT CO/CA/

https://www.streetinsider.com/SEC+Filings/Form+SCHEDULE+13GA+Pulmonx+Corp+Filed+by%3A+PRIMECAP+MANAGEMENT+COCA/27299103.html
PRIMECAP MANAGEMENT CO/CA/ filed an amended Schedule 13G/A for Pulmonx Corp, reporting beneficial ownership of 4,408,431 shares, representing 10.26% of the class. The filing indicates PRIMECAP has sole voting power over 4,373,231 shares and sole dispositive power over 4,408,431 shares. This statement confirms that the securities were acquired in the ordinary course of business and not for the purpose of influencing control of the issuer.

Pulmonx (LUNG) Stock Price, Chart & Analysis

https://www.debelegger.nl/en/stock/LUNG.US
This article provides a detailed analysis of Pulmonx (LUNG) stock, including its latest price of $2.56, market cap of $119.53M, and key financial figures. It evaluates the company's quality, growth, and valuation based on various metrics and offers a "Belegger score" using Buffett and Lynch's methods, rating it as weak overall. The analysis also includes analyst forecasts, peer comparisons, and a worked example of potential price targets under different scenarios.
Advertisement

Pulmonx 3Q 2026: Revenue $22.84M, Net income ($8.39M), EPS ($0.19) — 10-Q Summary

https://www.tradingview.com/news/tradingview:1a5971fc8f030:0-pulmonx-3q-2026-revenue-22-84m-net-income-8-39m-eps-0-19-10-q-summary/
Pulmonx reported its third-quarter 2026 financial results, with revenue increasing by 6.2% to $22.84 million compared to the prior-year quarter. The company also saw an improvement in its net loss, which narrowed to $8.39 million, and diluted loss per share, which improved to $0.19. Growth was primarily driven by higher Zephyr Valve procedure volumes in both U.S. and international markets, though nine-month revenue saw a slight decline due to lower U.S. volumes and a pause in China shipments.

Pulmonx Corporation (LUNG) Seasonal returns chart

https://uk.finance.yahoo.com/quote/LUNG/seasonality/
This article from Yahoo Finance presents a seasonal returns chart for Pulmonx Corporation (LUNG), showing the average monthly price return between 2020 and 2026. The stock closed at $3.0050, down 5.06%, and further decreased to $2.9800 after hours. The page also includes general market data and related tickers.

Pulmonx Corporation (LUNG) Stock Price, News, Quote & History

https://ca.finance.yahoo.com/quote/LUNG/
Pulmonx Corporation (LUNG) saw its stock price increase by 25.60% at close on October 29, with an overnight gain of 2.69%. The medical technology company, which specializes in treatments for severe emphysema, reported a YTD return of 43.21% and a 1-year return of 64.84%. Analysts have an average target price of $3.70 for LUNG, with Stifel recently raising its price target to $4.

Pulmonx (LUNG) Q3 2026 Earnings Call: Revenue Returns to Growth

https://www.tradingkey.com/news/transcripts/262244109-tradingkey
Pulmonx (LUNG) reported a significant return to revenue growth in Q3 2026, with worldwide revenue reaching $22.8 million, a 6% increase year-over-year. This growth was driven by improved commercial execution in the U.S. and strong international performance, excluding China. The company also narrowed its adjusted EBITDA loss by nearly 60% and reaffirmed its full-year 2026 revenue guidance.

Pulmonx to Participate in Upcoming Investor Conferences

https://ca.finance.yahoo.com/news/pulmonx-participate-upcoming-investor-conferences-200500276.html
Pulmonx Corporation announced its participation in two upcoming investor conferences: the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum and the Stifel 2026 Healthcare Conference, both scheduled for Wednesday, November 11. Management will engage in fireside chats and one-on-one meetings, with webcasts of the fireside chats available on the company's investor relations website. Pulmonx, a leader in minimally invasive treatments for severe lung disease, will discuss its products like the Zephyr Endobronchial Valve.
Advertisement

Pulmonx to Participate in Two Investor Conferences Nov. 11

https://www.stocktitan.net/news/LUNG/pulmonx-to-participate-in-upcoming-investor-9e42gq3uvbmq.html
Pulmonx (Nasdaq: LUNG) announced its management will participate in two investor conferences on November 11, featuring fireside chats and one-on-one meetings. The company will be present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum, and the Stifel 2026 Healthcare Conference. Live and archived webcasts of the fireside chats will be accessible on Pulmonx’s investor website.

Pulmonx Q3 2026 Earnings Call Transcript

https://www.benzinga.com/news/26/10/62640575/pulmonx-q3-2026-earnings-call-transcript
Pulmonx Corporation reported Q3 2026 worldwide revenue of $22.8 million, a 6% year-over-year increase, marking a return to growth. The company also significantly reduced its adjusted EBITDA loss by nearly 60% to $3.5 million, reflecting improved operating leverage and cost management. Pulmonx reiterated its full-year 2026 revenue guidance of $90 million to $92 million, driven by a refocused commercial strategy and increased salesforce productivity, with continued investment in clinical programs like Aeroseal.

Pulmonx Q3 Revenue Rises 6% to $22.8 Million; Net Loss Narrows to $8.4 Million

https://www.tradingview.com/news/tradingview:1b7c912c8188a:0-pulmonx-q3-revenue-rises-6-to-22-8-million-net-loss-narrows-to-8-4-million/
Pulmonx (LUNG) reported a 6% year-over-year increase in third-quarter 2026 revenue, reaching $22.8 million. The company's net loss narrowed to $8.4 million, and its Adjusted EBITDA loss also improved to $3.5 million. Pulmonx maintained its full-year revenue outlook and adjusted expectations for gross margin and operating expenses.

Pulmonx Revenue Rises 6% to $22.8 Million in Third Quarter 2026

https://www.quiverquant.com/news/Pulmonx+Revenue+Rises+6%25+to+%2422.8+Million+in+Third+Quarter+2026
Pulmonx Corporation (Nasdaq: LUNG) reported a 6% increase in third-quarter 2026 revenue, reaching $22.8 million. Despite this growth, the company posted a GAAP net loss of $8.4 million. Pulmonx maintained its full-year 2026 revenue outlook of $90 million to $92 million, with operating expenses expected to be $108 million to $109 million.

Form 8K Pulmonx Corp For: 27 October By Investing.com

https://uk.investing.com/news/stock-market-news/form-8k-pulmonxcorp-for-27-october-93CH-4935343
This article announces that Pulmonx Corp filed a Form 8K on October 27. The brief report highlights the filing of the Form 8K and includes a Reuters copyright notice, a link to view comments, and the stock ticker LUNG with a +4.04% change.
Advertisement

A quarterly loss fell 40% to $8.4 million at Pulmonx.

https://www.stocktitan.net/news/LUNG/pulmonx-reports-third-quarter-2026-financial-qcw9dwz11cwi.html
Pulmonx reported third-quarter 2026 revenue of $22.8 million, a 6% increase year-over-year, and significantly reduced its net loss by 40% to $8.4 million. The company's operating expenses also decreased by 18% to $24.9 million. Pulmonx reaffirmed its full-year 2026 revenue guidance of $90 million to $92 million and expects approximately 77% gross margin.

Pulmonx Corp. Estimates – MUN:4NI

https://www.tradingview.com/symbols/MUN-4NI/financials-estimates/?category=balance_sheet
This article provides access to financial actuals and analyst estimates for Pulmonx Corp. (MUN:4NI) on the Munich Stock Exchange. Users can explore reported financial data and compare it with average, high, and low estimates across income statements, balance sheets, cash flow statements, and valuation metrics, visualizing trends over time. The platform also offers annual and quarterly views of this data.

MarketScreener lists USD 3.40 average target for Pulmonx stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/marketscreener-lists-usd-3-40-average-target-for-pulmonx-stock/70377175
MarketScreener has set an average target of USD 3.40 for Pulmonx stock, based on analyses from five different analysts. This target represents an 84.78 percent premium over the Nasdaq quote of USD 1.84 as of October 20, 2026. Pulmonx, with ISIN US7458481014 and ticker LUNG, reported Q2 2026 revenue of USD 22.76 million and a net loss of USD 10.08 million, and is scheduled to release its Q3 2026 results on October 27, 2026.

Analysts set USD 3.50 target for Pulmonx stock, 96.63 percent above price

https://www.ad-hoc-news.de/boerse/news/nebenwerte/analysts-set-usd-3-50-target-for-pulmonx-stock-96-63-percent-above-price/70351294
Analysts have set an average price target of USD 3.50 for Pulmonx (PULM), representing a 96.63 percent increase from its October 16, 2026, closing price of USD 1.78. The company reported Q2 2026 revenue of USD 22.76 million and a net loss of USD 10.08 million, and is scheduled to release its Q3 2026 results on October 27, 2026. The stock's market capitalization stands at USD 76.4 million, with a consensus of three buy ratings and one hold from four analysts.

Pulmonx stock has October 27, 2026 results date

https://www.ad-hoc-news.de/boerse/news/nebenwerte/pulmonx-stock-has-october-27-2026-results-date/70332720
Pulmonx has scheduled its third-quarter results for October 27, 2026, which will be a key event for the medical device company. The stock was trading at EUR 1.62 on October 15, 2026, with a market capitalization of USD 78.2 million, and its main products include the Zephyr Valve, Chartis Pulmonary Assessment System, and StratX Lung Analysis Platform. The upcoming report will provide an update on the company's financial performance, following a second-quarter revenue of USD 22.8 million and a diluted loss of USD 0.24 per share.
Advertisement

Pulmonx to Report Third Quarter 2026 Financial Results on October 27, 2026

https://finance.yahoo.com/healthcare/articles/pulmonx-report-third-quarter-2026-200500262.html
Pulmonx Corporation announced it will release its financial results for the third quarter of 2026 after the market closes on Tuesday, October 27, 2026. Company management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss these results. A live webcast will be available on the "Investors" section of the Pulmonx website.

Pulmonx to Report Third Quarter 2026 Financial Results on October 27, 2026

https://www.manilatimes.net/2026/10/14/tmt-newswire/globenewswire/pulmonx-to-report-third-quarter-2026-financial-results-on-october-27-2026/2445069
Pulmonx Corporation announced it will release its third-quarter 2026 financial results after market close on Tuesday, October 27, 2026. The company will also host a conference call on the same day at 1:30 p.m. PT / 4:30 p.m. ET to discuss these results. A webcast of the event will be available on their investor relations website.

Pulmonx Corp (LUNG-Q) Stock Price and News

https://www.theglobeandmail.com/investing/markets/stocks/LUNG/
This article provides current stock information for Pulmonx Corp (LUNG-Q), including its NASDAQ ticker, real-time price updates, and recent trading data. It also includes a news feed with analyst ratings, earnings call transcripts, and corporate announcements related to the company. Pulmonx Corporation is described as a medical technology company specializing in minimally invasive devices for chronic obstructive pulmonary diseases, based in Redwood City, California.

Pulmonx CCO Geoffrey Rose sells $17,804 in lung shares

https://www.investing.com/news/insider-trading-news/pulmonx-cco-geoffrey-rose-sells-17804-in-lung-shares-93CH-4888694
Geoffrey Rose, Chief Commercial Officer at Pulmonx Corp (NASDAQ:LUNG), sold 7,879 shares of company stock for a total of $17,804 on September 1, 2026. These sales were primarily conducted to cover tax withholding obligations related to the vesting of his Restricted Stock Units (RSUs). Following these transactions, Rose still directly holds 449,832 shares, and the company's stock has recently shown strong momentum, delivering a 48% return over the past six months and appearing undervalued according to InvestingPro analysis.

Four new hires get 52,300 stock units from Pulmonx

https://www.stocktitan.net/news/LUNG/pulmonx-corporation-announces-inducement-grants-under-nasdaq-listing-mzf4k3a5kav7.html
Pulmonx (Nasdaq: LUNG) announced it granted 52,300 restricted stock units (RSUs) to four new employees hired in the third fiscal quarter of 2026. These equity awards were granted on September 1, 2026, under its 2025 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with one-fourth vesting on the first anniversary of the grant date and the remainder in equal quarterly installments over the subsequent three years, subject to continuous employment.
Advertisement

Pulmonx chief science officer sells $32,192 in stock

https://www.investing.com/news/insider-trading-news/pulmonx-chief-science-officer-sells-32192-in-stock-93CH-4888698
Pulmonx's Chief Science & Technology Officer, Srikanth Radhakrishnan, sold 14,245 shares of common stock for a total of $32,192 to cover tax withholding obligations related to vested Restricted Stock Units. These sales occurred on September 1, 2026, at a price of $2.26 per share. Following these transactions, Mr. Radhakrishnan directly owns 316,994 shares, and the company's stock has seen a 48% return over the last six months.

Pulmonx general counsel David Lehman sells $32,393 in stock

https://www.investing.com/news/insider-trading-news/pulmonx-general-counsel-david-lehman-sells-32393-in-stock-93CH-4888693
David Lehman, General Counsel of Pulmonx Corp (NASDAQ:LUNG), sold 14,334 shares of company stock totaling $32,393 on September 1, 2026. These sales were primarily to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs). Following these transactions, Lehman directly holds 361,827 shares, with the stock currently trading at $2.26.

Pulmonx Corp Officer Radhakrishnan Srikanth Sells 14,245 Shares at $2.26 Each (NASDAQ: LUNG)

https://kalkinemedia.com/us/news/announcements/pulmonx-corp-officer-radhakrishnan-srikanth-sells-14245-shares-at-226-each-nasdaq-lung
Radhakrishnan Srikanth, Chief Science & Technology Officer of Pulmonx Corp (NASDAQ: LUNG), sold 14,245 shares of the company stock in four separate transactions on September 1, 2026, at a price of $2.26 per share. Following these sales, Srikanth retains ownership of 316,994 shares of Pulmonx Corp. All transactions were filed with the SEC under transaction code S.

Pulmonx (LUNG) general counsel sells shares to cover RSU taxes

https://www.stocktitan.net/sec-filings/LUNG/form-4-pulmonx-corp-insider-trading-activity-2ab4e0cebb6b.html
Pulmonx Corp's General Counsel, David Aaron Lehman, sold 14,334 shares of common stock on September 1, 2026, for $2.26 per share across four transactions. These sales were made to cover tax withholding obligations arising from the vesting of Restricted Stock Units granted between 2023 and 2026. After these transactions, Lehman directly holds 361,827 shares of common stock.

Pulmonx general counsel David Lehman sells $32,393 in stock By Investing.com

https://ng.investing.com/news/stock-market-news/pulmonx-general-counsel-david-lehman-sells-32393-in-stock-93CH-2685231
David Lehman, General Counsel of Pulmonx Corp (NASDAQ:LUNG), sold 14,334 shares of company stock totaling $32,393 on September 1, 2026. These sales were executed to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs) granted between 2023 and 2026. Following these transactions, Lehman directly holds 361,827 shares, while the company's stock trades at $2.26, showing a 48% increase over six months.
Advertisement

Pulmonx (LUNG) exec sells shares to cover RSU taxes

https://www.stocktitan.net/sec-filings/LUNG/form-4-pulmonx-corp-insider-trading-activity-8c4867c11303.html
Pulmonx's Chief Commercial Officer, Rose Geoffrey Beran, sold 7,879 shares of common stock at $2.26 per share on September 1, 2026. These sales were not discretionary but were made to cover tax withholding obligations arising from the vesting of Restricted Stock Units granted between 2023 and 2026. The filing indicates a neutral impact but negative sentiment, confirming the transactions were for tax purposes and not under a Rule 10b5-1 trading plan.

Pulmonx (LUNG) CEO sells 41,882 shares to cover taxes

https://www.stocktitan.net/sec-filings/LUNG/form-4-pulmonx-corp-insider-trading-activity-36931bd106b5.html
Pulmonx Corp's President and CEO, Glendon E. French III, sold 41,882 shares of common stock at $2.26 per share on September 1, 2026. These sales were conducted to cover tax withholding obligations arising from the vesting of Restricted Stock Units granted in 2023 and 2025. Following these transactions, French indirectly holds 918,198 shares through a family trust, and the sales were not made under a Rule 10b5-1 trading plan.

Pulmonx CEO French Glendon E. III Disposes of 41,882 Shares at $2.26 Each

https://kalkinemedia.com/us/news/announcements/pulmonx-ceo-french-glendon-e-iii-disposes-of-41882-shares-at-226-each
Pulmonx Corp's President and CEO, French Glendon E. III, sold 41,882 shares at $2.26 each in two separate transactions on September 1, 2026. Following these sales, his ownership stake in Pulmonx Corp (NASDAQ: LUNG) is 1,137,936 shares. These transactions were reported under SEC transaction code S.

Pulmonx general counsel David Lehman sells $32,393 in stock

https://m.investing.com/news/insider-trading-news/pulmonx-general-counsel-david-lehman-sells-32393-in-stock-93CH-4888693?ampMode=1
David Aaron Lehman, General Counsel of Pulmonx Corp (NASDAQ:LUNG), sold 14,334 shares of company stock for a total of $32,393 on September 1, 2026. These sales were primarily to cover tax withholding obligations related to vested Restricted Stock Units (RSUs) granted over several years. Following the transactions, Lehman directly holds 361,827 shares, as Pulmonx shares have seen a 48% increase over the past six months, despite a recent 7% decline, and the company reported better-than-expected Q2 2026 financial results.

Pulmonx chief science officer sells $32,192 in stock

https://m.investing.com/news/insider-trading-news/pulmonx-chief-science-officer-sells-32192-in-stock-93CH-4888698?ampMode=1
Pulmonx's Chief Science & Technology Officer, Srikanth Radhakrishnan, sold 14,245 shares of company stock for $32,192 to cover tax withholding obligations from RSU vestings. Despite the sale, Radhakrishnan still directly owns 316,994 shares. The company recently surpassed analyst expectations for its Q2 2026 earnings, contributing to a strong 48% return for LUNG shares over the past six months, although InvestingPro suggests the stock is still undervalued.
Advertisement

Pulmonx CCO Geoffrey Rose sells $17,804 in lung shares

https://m.investing.com/news/insider-trading-news/pulmonx-cco-geoffrey-rose-sells-17804-in-lung-shares-93CH-4888694?ampMode=1
Pulmonx's Chief Commercial Officer, Geoffrey Rose, sold 7,879 shares of the company's common stock for $17,804 to cover tax obligations from vested Restricted Stock Units. Following these sales, he still directly holds 449,832 shares. This insider transaction comes as LUNG stock has seen significant growth and the company recently surpassed Q2 2026 financial expectations.

Insider at Pulmonx (LUNG) sells shares to cover taxes

https://www.stocktitan.net/sec-filings/LUNG/form-4-pulmonx-corp-insider-trading-activity-481427302119.html
Pulmonx's Chief Science & Technology Officer, Radhakrishnan Srikanth, sold 14,245 shares of common stock at $2.26 per share on September 1, 2026. These sales were executed across four transactions to cover tax withholding obligations arising from the vesting of Restricted Stock Units granted between March 2023 and March 2026. The filing indicates no Rule 10b5-1 trading plan was in place for these transactions.

Pulmonx to Participate in Upcoming Investor Conferences

https://finance.yahoo.com/healthcare/articles/pulmonx-participate-upcoming-investor-conferences-200500151.html
Pulmonx Corporation announced its participation in two upcoming investor conferences: the Wells Fargo Healthcare Conference on September 9 in Boston, and the Lake Street Best Ideas Growth (BIG10) Conference on September 10 in New York, both featuring 1x1 meetings. The company, a leader in minimally invasive treatments for severe lung disease, will have its management present at these events. Pulmonx is known for its Zephyr® Endobronchial Valve and other related systems for treating COPD.

Pulmonx Corp. Revenue Breakdown – LS:A2P1AF

https://www.tradingview.com/symbols/LS-A2P1AF/financials-segments/
Pulmonx Corp. (A2P1AF) generated 77.05 million EUR in revenue last year, primarily from its Interventional Pulmonology segment. This marks a slight decrease from the previous year's revenue of 80.94 million EUR. The United States was the largest contributor to revenue, accounting for 48.55 million EUR.

What Makes Pulmonx Corporation (LUNG) a Strong Momentum Stock: Buy Now?

https://ca.finance.yahoo.com/news/makes-pulmonx-corporation-lung-strong-160005833.html
Pulmonx Corporation (LUNG) has been identified as a strong momentum stock by Zacks Equity Research, boasting a Momentum Style Score of B and a Zacks Rank of #2 (Buy). The company has shown significant short-term and long-term price performance, outperforming both its industry and the S&P 500. Positive earnings estimate revisions further contribute to its promising outlook for investors seeking near-term growth.
Advertisement

Morgan Stanley (LUNG) reports 6.9% Pulmonx stake in updated ownership filing

https://www.stocktitan.net/sec-filings/LUNG/schedule-13g-a-pulmonx-corp-amended-passive-investment-disclosure-86a2be004992.html
Morgan Stanley and Morgan Stanley Capital Services LLC have filed an amended Schedule 13G, disclosing their beneficial ownership in Pulmonx Corp (LUNG). Morgan Stanley reports a 6.9% stake, representing 2,920,241 shares, while Morgan Stanley Capital Services LLC reports a 6.8% stake, or 2,885,147 shares. All reported shares are held with shared voting and dispositive power.

Pulmonx (LUNG) Q2 2026 Earnings Call Transcript

https://www.theglobeandmail.com/investing/markets/stocks/LUNG-Q/pressreleases/3730523/pulmonx-lung-q2-2026-earnings-call-transcript/
Pulmonx (LUNG) reported its Q2 2026 earnings, highlighting a 34% reduction in net loss and a 39% decrease in adjusted EBITDA loss, driven by cost alignment initiatives. The company reiterated its full-year revenue guidance of $90 million to $92 million and expects to return to year-over-year sales growth later in 2026, partly due to the renewal of its Chinese registration certificate and stabilizing U.S. sales force. Pulmonx also emphasized the potential of its AeriSeal product to expand the total addressable market by approximately 20% globally, with CONVERT II trial enrollment on track for completion in 2027.

Pulmonx Corp 2026: Revenue $22.76M, EPS ($0.24) — 10-Q Summary

https://www.tradingview.com/news/tradingview:cb3cf9e601a44:0-pulmonx-corp-2026-revenue-22-76m-eps-0-24-10-q-summary/
Pulmonx Corp reported its 2026 quarterly results, showing revenue of $22.76 million and a diluted EPS of ($0.24), an improvement from the prior year. The company experienced a decline in revenue due to lower procedure volumes, particularly in the U.S. and China, but saw an improved gross margin and continued commercial expansion efforts.

Pulmonx (LUNG) Upgraded to Buy: What Does It Mean for the Stock?

https://finance.yahoo.com/markets/stocks/articles/pulmonx-lung-upgraded-buy-does-160006154.html
Pulmonx (LUNG) has been upgraded to a Zacks Rank #2 (Buy) due to an upward trend in earnings estimates. The Zacks rating system highlights the strong correlation between changes in future earnings potential and near-term stock price movements, suggesting positive investor sentiment and potential for stock appreciation. This upgrade places Pulmonx in the top 20% of Zacks-covered stocks based on estimate revisions, indicating a strong candidate for market-beating returns.

Earnings Release: Here's Why Analysts Cut Their Pulmonx Corporation (NASDAQ:LUNG) Price Target To US$3.40

https://www.sahmcapital.com/news/content/earnings-release-heres-why-analysts-cut-their-pulmonx-corporation-nasdaqlung-price-target-to-us340-2026-08-01
Pulmonx Corporation's Q2 results showed revenues in line with predictions and smaller-than-expected statutory losses. Despite the positive earnings surprise, analysts have lowered their average price target to US$3.40, indicating reduced optimism about the company's future valuation. While revenue growth is expected to slow, it is still projected to align with the industry average.
Advertisement

Lake Street Maintains Pulmonx(LUNG.US) With Buy Rating, Maintains Target Price $4

https://www.moomoo.com/news/post/73822293/lake-street-maintains-pulmonx-lungus-with-buy-rating-maintains-target
Lake Street has reiterated its Buy rating for Pulmonx (LUNG.US) and maintained its price target at $4. This indicates a continued positive outlook from the firm regarding the company's stock performance.

Pulmonx Affirms FY26 Sales Guidance of $90.000M-$92.000M

https://scanx.trade/stock-market-news/companies/pulmonx-affirms-fy26-sales-guidance-of-90-000m-92-000m/46919988
Pulmonx (NASDAQ: LUNG) has reiterated its full-year 2026 sales guidance, keeping the range at $90.000 million to $92.000 million. This guidance is consistent with previous statements and aligns closely with the consensus analyst estimate of $90.832 million. The affirmation signals management's confidence in the company's operational performance and ability to meet financial targets for the fiscal year.

Pulmonx Corp Q2 revenue falls, but beats estimates

https://www.tradingview.com/news/reuters.com,2026:newsml_L1N43V1DO:0-pulmonx-corp-q2-revenue-falls-but-beats-estimates/
Pulmonx Corp's Q2 revenue experienced a decline but still managed to surpass analyst estimates. The article, sourced from Reuters via TradingView News, provides a brief update on the company's financial performance.

Pulmonx Corporation (LUNG) Reports Q2 Loss, Beats Revenue Estimates

https://finance.yahoo.com/markets/stocks/articles/pulmonx-corporation-lung-reports-q2-212506997.html
Pulmonx Corporation (LUNG) reported a Q2 loss of $0.24 per share, surpassing the Zacks Consensus Estimate of a $0.28 loss, and also beat revenue expectations with $22.76 million. Despite underperforming the market year-to-date, the company has consistently topped revenue estimates in the past four quarters, and its stock currently holds a Zacks Rank #3 (Hold).

LUNG|Pulmonx Corp|Price:1.245|Chg%:-0.005

https://www.tradingkey.com/markets/stocks/lung/financials
This article provides a detailed financial overview of Pulmonx Corp (LUNG), including its stock performance, key financial indicators, and historical data. It presents an all-in-one data dashboard for smart investors, organizing complex financial statements into customizable views. The report covers the income statement, balance sheet, and cash flow statement, highlighting the latest annual financial report and quarterly performance breakdowns.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement